

# Karen L Rech

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/847107/publications.pdf>

Version: 2024-02-01

38  
papers

1,678  
citations

759233

12  
h-index

501196

28  
g-index

38  
all docs

38  
docs citations

38  
times ranked

696  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. <i>Oncologist</i> , 2022, 27, 144-148.	3.7	3
2	Histiocyte-rich pseudotumor " a post-chemotherapy radiologic dilemma. <i>Journal of Hematopathology</i> , 2022, 15, 45.	0.4	0
3	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 156-164.	3.0	5
4	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. <i>Blood</i> , 2022, 139, 2601-2621.	1.4	63
5	Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 125, 2-10.	2.0	2
6	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	3
7	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.2	1,023
8	Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E146-E150.	4.1	21
9	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7049-7049.	1.6	0
10	<i>BRAF</i> <sup>V600E</sup> frequency and impact on outcomes in adults with langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7050-7050.	1.6	0
11	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. <i>American Journal of Hematology</i> , 2021, 96, 1604-1610.	4.1	18
12	Efficacy of Cobimetinib in Rosai-Dorfman Disease. <i>Blood</i> , 2021, 138, 1506-1506.	1.4	1
13	Transformation of Follicular Lymphoma into Primary Mediastinal B-Cell Lymphoma-like Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4479-4479.	1.4	0
14	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. <i>Blood</i> , 2021, 138, 2566-2566.	1.4	0
15	Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1305-1311.	4.9	9
16	Tumor Mutational Burden in Histiocytic Neoplasms. <i>Blood</i> , 2021, 138, 3634-3634.	1.4	0
17	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	3.5	105
18	Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 241-249.	2.5	31

#	ARTICLE	IF	CITATIONS
19	Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. <i>Leukemia and Lymphoma</i> , 2020, 61, 975-978.	1.3	7
20	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF</i> <i>V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. <i>Oncologist</i> , 2020, 25, 1001-1004.	3.7	25
21	Low-dose vemurafenib monotherapy in <i>BRAF</i> <sup>V600E</sup> -mutated Erdheim-Chester disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 2733-2737.	1.3	9
22	Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. <i>American Journal of Clinical Pathology</i> , 2020, 154, 767-775.	0.7	1
23	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1852-1864.	3.0	105
24	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e84-e86.	3.5	12
25	The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis. <i>Blood</i> , 2020, 136, 45-45.	1.4	0
26	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 10-12.	1.4	0
27	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and <i>DUSP22</i> rearrangements in Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	0
28	Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. <i>British Journal of Haematology</i> , 2019, 187, e51-e54.	2.5	13
29	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2054-2071.	3.0	116
30	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 441-446.	0.4	9
31	Î±1-Heavy Chain Deposition Disease With Negative Immunofluorescence Staining on Renal Biopsy. <i>Kidney International Reports</i> , 2019, 4, 178-183.	0.8	0
32	Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis. <i>Blood</i> , 2019, 134, 1667-1667.	1.4	2
33	Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation. <i>Blood</i> , 2019, 134, 5895-5895.	1.4	2
34	Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. <i>British Journal of Haematology</i> , 2018, 182, 579-581.	2.5	43
35	Florid dermatopathic lymphadenopathy-A morphological mimic of Langerhans cell histiocytosis. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1637-1638.	0.5	6
36	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018, 132, 586-586.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. <i>Blood</i> , 2018, 132, 1112-1112.	1.4	1
38	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <i>Human Pathology</i> , 2017, 64, 19-27.	2.0	41